You are here:

alemtuzumab (Lemtrada)

Advice

following a full submission

alemtuzumab (Lemtrada®) is accepted for use within NHS Scotland.

Indication under review: For adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

Two phase III studies comparing alemtuzumab with interferon beta-1a in treatment-naive (CARE-MS I) and treatment-experienced (CARE-MS II) patients with relapsing remitting multiple sclerosis both showed a statistically significant relative decrease in relapse rate of 55% and 49% respectively in favour of alemtuzumab. There was a significant reduction in the risk of sustained accumulation of disability over 6 months of 42% in CARE-MS II, but for CARE-MS-I, this was not statistically significant.

Drug Details

Drug Name: alemtuzumab (Lemtrada)
SMC Drug ID: 959/14
Manufacturer: Genzyme Therapeutics Ltd
Indication: For adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 July 2014

Back